Gregory Craven

Gregory Craven is an Assistant Professor of Molecular, Cellular & Developmental Biology at Yale University. He earned a first-class degree in Chemistry from the University of Oxford and completed his Ph.D. at Imperial College London, working with Professors David Mann, Alan Armstrong, and Ed Tate. His doctoral research focused on fragment-based drug discovery and cysteine targeting. He then conducted postdoctoral research at the University of California, San Francisco with Professor Jack Taunton, where he developed lysine-targeted covalent inhibitors and chemoproteomic methods. His work led to the discovery of the first mutant-selective inhibitor of AKT1(E17K), a common driver of breast cancer. The Craven lab designs small molecule inhibitors and chemical tools to probe and perturb dysregulated signaling pathways, especially in cancer.

Gregory B Craven is a chemical biologist at Yale University whose research focuses on developing novel chemical tools and strategies to probe biological systems. His work integrates chemical biology with structural and functional studies to understand molecular mechanisms and identify therapeutic targets. Craven's research includes the design of covalent inhibitors, reversible probes, and high-throughput screening methods to study protein-ligand interactions and enzyme activity. His studies span diverse areas such as kinase inhibition, GTPase function, and viral protease inhibition, with a focus on structural insights and functional outcomes. His work has contributed to the discovery of covalent ligands and the development of targeted inhibitors for diseases such as cancer and viral infections.